成都先導(688222.SH):探索了多種AI藥物預測、分子生成和優化模型
格隆匯3月21日丨成都先導(688222.SH)在互動平台表示,2021年,公司與Cambridge Molecular(劍橋小分子)宣佈建立獨家聯盟,在成都先導世界領先的DNA編碼化合物庫(DEL)技術平台上,結合Cambridge Molecular為DEL高度優化的深度機器學習系統 - DeepDELve 2,為藥物靶點高效提供具有潛在活性、更易得的化合物,加快化合物的活性驗證和拓寬化合物空間。成都先導在此基礎上,進一步探索了多種AI藥物預測、分子生成和優化模型,通過先導自有的海量DEL篩選數據進行優化和迭代,能更為準確地提供多類靶點的化合物活性預測,並向客户提供服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.